Pharma News

Even after causing havoc for last two years, coronavirus seems to have been refusing to die down. 

The FDA has approved UCB’s Fintepla (flenfuramine) for patients two years and older experiencing seizures associated with Lennox-Gastaut syndrome.

The FDA has pushed back its decision date on Bristol Myers Squibb’s (BMS) supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt) for the treatment of patients with non...

Moderna said it expects to earn approximately $21 billion from sales of its COVID-19 vaccine, Spikevax, this year, based on its advance purchase agreements.  ...

Washington (AFP) – A team of scientists said  they had developed an oral male contraceptive that is 99 percent effective in mice without causing side effects, and could enter human trials by...

With the help of some of the best tweezers in the world, a team of researchers from the University of Copenhagen has shed new light on a fundamental mechanism in all living cells that helps them ex...

The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices.

A study published today in Nature Communications unveils a new platform for discovering cellular signatures of disease that integrates robotic systems for studying patient cells with artificial int...

The results show that all three ADAs studied (domperidone, metopimazine, and metoclopramide) were associated with an increased risk, especially in the first days of use, but the highest increase w...

Teva Pharmaceuticals has halted a phase 2 trial of TEV-48574, an investigational biologic drug for asthma patients, after interim results indicated that the treatment is unlikely to provide a signi...

An Aurobindo plant that received a scathing FDA rebuke several years back is shutting its doors for good.

Novartis has pushed its second radioligand therapy over the FDA finish line, and the Swiss pharma has more than $2 billion in peak sales expectation linked to the new launch. ...